ReviewTrends in neurosciences2023
The foundation and architecture of precision medicine in neurology and psychiatry.
Review in Trends in neurosciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 2 syntheses or guidelines pooled it, 125 citations in OpenAlex.
- Lipidomics and genomics in mental health: insights into major depressive disorder, bipolar disorder, schizophrenia, and obsessive-compulsive disorder.Lipids in health and disease · 2025Pooled it
- Neuroscience meets behavior: A systematic literature review on magnetic resonance imaging of the brain combined with real-world digital phenotyping.Human brain mapping · 2024Pooled it
- Multimodal prognostic modeling of individual cognitive trajectories to enhance trial efficiency in preclinical Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Trial
- Effects of Oral Contraceptive Pills on Brain Networks: A Conceptual Replication and Extension.Human brain mapping · 2025Trial
- Differential response to donepezil in MRI subtypes of mild cognitive impairment.Alzheimer's research & therapy · 2023Trial
- Neuromodulation for restoring and amplifying brain function.Nature neuroscience · 2026Review
- Clinical innovations and future directions of nanoparticles in the treatment of psychiatric and neurological disorders.Molecular psychiatry · 2026Review
- Dissecting the Ecological Structure of Health and Disease in the Global Gut Microbiome.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Evaluating digital cognitive tests for clinical use in Alzheimer's disease: A novel framework and scoping review.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Aberrant neuronal differentiation and splicing defects in Congenital Myotonic Dystrophy (DM1) iPSC models.bioRxiv : the preprint server for biology · 2026Article
- EEG Signatures of Melancholia: An Update.NeuroSci · 2026Review
- How to Foster Challenging Interdisciplinary Collaborations: Can Philosophy Support Neuroscientists?The European journal of neuroscience · 2026Review
- Value drivers and barriers to the adoption of Precision Psychiatry in Latin America: a qualitative study.BMC psychiatry · 2026Article
- Clinical deep phenotyping of treatment response in schizophrenia (CDP-STAR): design and methodology of a prospective multimodal observational study.European archives of psychiatry and clinical neuroscience · 2026Observational
- Personalizing Relapsing-Remitting Multiple Sclerosis Monitoring: Patient Acceptance of Serum Neurofilament Light Chain and the Role of Disease Knowledge.Journal of personalized medicine · 2026Article
- New Personalized Medicine Model for Medication Management.Journal of personalized medicine · 2026Review
- TYK2 mediates neuroinflammation in Alzheimer's disease brains with TDP-43 pathology.Nature communications · 2026Article
- Companion Diagnostics in Clinical Therapy: Current Applications and Future Directions.MedComm · 2026Review
- Advancing Early Detection of Alzheimer Disease in the Primary Care Setting in the United States.Neurology. Clinical practice · 2026Article
- The role of brain health and resilience in reshaping trajectories of late-life neuropsychiatric disorders.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Review
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
Abstract
Neurological and psychiatric diseases have high degrees of genetic and pathophysiological heterogeneity, irrespective of clinical manifestations. Traditional medical paradigms have focused on late-stage syndromic aspects of these diseases, with little consideration of the underlying biology. Advances in disease modeling and methodological design have paved the way for the development of precision medicine (PM), an established concept in oncology with growing attention from other medical specialties. We propose a PM architecture for central nervous system diseases built on four converging pillars: multimodal biomarkers, systems medicine, digital health technologies, and data science. We discuss Alzheimer's disease (AD), an area of significant unmet medical need, as a case-in-point for the proposed framework. AD can be seen as one of the most advanced PM-oriented disease models and as a compelling catalyzer towards PM-oriented neuroscience drug development and advanced healthcare practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.